AVEO Pharmaceuticals, Inc (AVEO)

Etorro trading 970x250
AVEO Pharmaceuticals, Inc (AVEO) Logo

About AVEO Pharmaceuticals, Inc

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company’s preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts. Address: 30 Winter Street, Boston, MA, United States, 02108

AVEO Pharmaceuticals, Inc News and around…

Latest news about AVEO Pharmaceuticals, Inc (AVEO) common stock and company :

AVEO Makes Bullish Cross Above Critical Moving Average
23 Sep, 2021 FinancialContent

In trading on Thursday, shares of AVEO Pharmaceuticals Inc (AVEO) crossed above their 200 day moving average of $7.01, changing hands as high as $7.06 per share. AVEO Pharmaceuticals Inc shares are currently trading up about 2.2% on the day..

AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
20 Sep, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor.

Great news for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Insiders acquired stock in large numbers last year
13 Sep, 2021 Yahoo! Finance

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
30 Aug, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences:

AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
05 Aug, 2021 Yahoo! Finance

AVEO (AVEO) delivered earnings and revenue surprises of -2.13% and -2.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: AVEO Pharmaceuticals Q2 Earnings
05 Aug, 2021 FinancialContent

Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results. Quarterly ...

AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
05 Aug, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021, and provided a business update.

AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
05 Aug, 2021 Yahoo! Finance

BOSTON, August 05, 2021--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021, and provided a business update.

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

AVEO Pharmaceuticals Becomes Oversold (AVEO)
29 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
29 Jul, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 5, 2021, to discuss the financial results and provide a business update.

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
11 Jul, 2021 FinancialContent

Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, ...

AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
08 Jul, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib), AVEO’s oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies, on Friday, July 16, 2021 at 12:00 p.m. Eastern Time.

AVEO Pharmaceuticals Enters Oversold Territory (AVEO)
06 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Notable Two Hundred Day Moving Average Cross - AVEO
15 Jun, 2021 FinancialContent

In trading on Tuesday, shares of AVEO Pharmaceuticals Inc (AVEO) crossed below their 200 day moving average of $6.89, changing hands as low as $6.81 per share. AVEO Pharmaceuticals Inc shares are currently trading down about 0.6% on the day..

AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
07 Jun, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF), being studied in head and neck squamous cell carcinoma (HNSCC) on Wednesday, June 16, 2021 at 2:00 p.m. Eastern Time.

Analysts Anticipate 22% Gains Ahead For VTWG
01 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $264.25 per unit.

AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
25 May, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time.

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
19 May, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the presentation of additional data from the Phase 3 TIVO-3 study comparing FOTIVDA® (tivozanib) to sorafenib in relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. The data, which includes updated durability of response (DOR) and overall survival (OS) results, as well as an analysis of treatment-emergent adverse events (TEAEs) across study arms, will be featured in two poster presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4-8 in a virtual setting. FOTIVDA, AVEO’s oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), is approved by the U.S. Food and Drug Administration for the treatment of adults with relapsed or refractory advanced RCC following two or more prior systemic therapies.

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
19 May, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of ficlatuzumab as a single agent or in combination with cetuximab (ERBITUX®), an EGFR-targeted antibody, in patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab (pan-refractory) with metastatic head and neck squamous cell carcinoma (HNSCC). Ficlatuzumab is AVEO’s potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF). The results will be presented by lead investigator Julie E. Bauman, M.D., MPH, Professor of Medicine, Chief, Division of Hematology/Oncology, Associate Director of Translational Research, Deputy Director, University of Arizona Cancer Center, at a poster discussion session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8 in a virtual setting.

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
10 May, 2021 Yahoo! Finance

AVEO (AVEO) delivered earnings and revenue surprises of -30.91% and 42.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
10 May, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

AVEO Pharmaceuticals, Inc. to Host Earnings Call
10 May, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / May 10, 2021 / AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time.

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
09 May, 2021 FinancialContent

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical ...

AVEO Makes Notable Cross Below Critical Moving Average
06 May, 2021 FinancialContent

In trading on Thursday, shares of AVEO Pharmaceuticals Inc (AVEO) crossed below their 200 day moving average of $6.57, changing hands as low as $6.43 per share. AVEO Pharmaceuticals Inc shares are currently trading off about 2.1% on the day..

AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
03 May, 2021 FinancialContent

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 10, 2021, to discuss the financial results and provide a business update.

Analysts See 14% Gains Ahead For VTWG
27 Apr, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $259.05 per unit.

Earnings Preview: AVEO Pharmaceuticals (AVEO) Q1 Earnings Expected to Decline
22 Apr, 2021 Yahoo! Finance

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

First Week of AVEO June 18th Options Trading
21 Apr, 2021 FinancialContent

Investors in AVEO Pharmaceuticals Inc (AVEO) saw new options become available this week, for the June 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new June 18th contracts and identified one put and one call contract of particular interest.

AVEO Pharmaceuticals, Inc (AVEO) is a NASDAQ Common Stock listed in , ,

970x250